| Document |
Document Title |
|
WO/2022/237627A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for...
|
|
WO/2022/236396A1 |
The invention relates to a self-preserving anti-microbial pharmaceutical composition, comprising a compound Alpha-1062 or salt thereof, wherein the composition is essentially absent of additional antimicrobial preservatives. The inventio...
|
|
WO/2022/236407A1 |
New psilocybin and psilocin conjugates and their soluble salts with synergistic or additive therapeutic agents and stable formulations thereof, as well as their medical applications. The synergistic or additive conjugates may be used as ...
|
|
WO/2022/240876A1 |
Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I),...
|
|
WO/2022/238816A1 |
Bicyclic heterocyclic compounds and derivatives thereof that have antiviral properties are disclosed. Pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for the delivery of the compounds to a subject...
|
|
WO/2022/237367A1 |
The present invention relates to a heterocyclic compound for inhibiting SHP2 activity that is as represented by general formula I, a preparation method therefor and the use thereof. The compound of the present invention can effectively t...
|
|
WO/2022/234298A1 |
Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of PKC-theta. Such compounds are represented by Formula I, wherein the variables are defined ...
|
|
WO/2022/234271A1 |
The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for α5-subunit-containing GABA...
|
|
WO/2022/233298A1 |
A method for extracting and separating high-purity tetrodotoxin (TTX) from pufferfish viscera, comprising the following steps: adding an acid alcohol homogenate to pufferfish viscera, adding a certain amount of a flow aid and stirring un...
|
|
WO/2022/236255A2 |
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2022/236101A1 |
Isoquinolinone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell...
|
|
WO/2022/236136A1 |
Disclosed herein, in part, are compounds (I) which are exatecan derivatives with novel chemical linkers that include cathepsin B cleavable moieties, and conjugated to targeting antibodies.
|
|
WO/2022/229341A1 |
The present invention relates to heterocyclic compounds of formula (I) capable of activat-ing STING (Stimulator of Interferon Genes).
|
|
WO/2022/226855A1 |
Disclosed in the present invention is a method for preparing pyrano[2,3-b]-indole-2-one without a catalyst, the method comprising: in the presence of DBU (1,8-diazabicyclo undec-7-ene), using an isatin compound and a cyclopropenone compo...
|
|
WO/2022/231164A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2022/232834A1 |
The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
|
|
WO/2022/229061A1 |
The present invention covers furoindazole compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7a and R7b are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compound...
|
|
WO/2022/226668A1 |
The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable ...
|
|
WO/2022/228489A1 |
The present invention relates a novel compound having cancer treatment activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound.
|
|
WO/2022/229234A1 |
The present invention relates to nitrogenous hetetocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/229126A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
|
|
WO/2022/229405A1 |
The present invention relates to new pyridine-sulfonamide derivatives of formula (I') as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the pr...
|
|
WO/2022/223689A1 |
The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicam...
|
|
WO/2022/225934A1 |
Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
|
WO/2022/225941A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/221866A1 |
The present invention provides MEK inhibitors of formula (I'), compositions thereof, and methods of using the same.
|
|
WO/2022/220163A1 |
[Problem] To provide, according to the present invention, a novel compound that binds specifically to an intracellular and/or extracellular vesicle, a mitochondria staining agent, and a method for fluorescent staining of mitochondria. Th...
|
|
WO/2022/219412A1 |
Disclosed herein, in part, is a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: (I) wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10...
|
|
WO/2022/219546A1 |
The present application relates to Leukotriene A4 hydrolase (LTA4H) inhibitors of formula (I), for use in the treatment of various disorders.
|
|
WO/2022/215020A1 |
The present invention relates to a novel 1,3,4-oxadiazole thiocarbonyl compound having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof for preparing a m...
|
|
WO/2022/215754A1 |
Provided is a bicyclic pyridine derivative. A compound represented by formula I [wherein: X represents an oxygen atom, a sulfur atom, NR or CR'R"; n is 0 or 1; R1, R2a, R2b, R2c, R2d, R, R' and R" independently represent a hydrogen atom,...
|
|
WO/2022/216573A1 |
Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, Z, m, n, p, and q are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions compris...
|
|
WO/2022/213854A1 |
The present invention relates to a series of carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I). The present carbazole derivative has high stability and triplet energy le...
|
|
WO/2022/214531A1 |
The present invention relates to new compounds of formula (I) as sigma ligands having a great affinity for sigma receptors, sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2). The present invention also refers to the process for the pr...
|
|
WO/2022/213896A1 |
The present invention provides a quinoxaline compound, a preparation method, and a pharmaceutical application thereof, and particularly relates to a quinoxaline compound having PAR4 antagonistic activity and a preparation method therefor...
|
|
WO/2022/206706A1 |
Provided are a spiro-containing derivative, and a preparation method therefor and the use thereof. In particular, provided are a compound as shown in general formula (I), and a preparation method therefor, a pharmaceutical composition co...
|
|
WO/2022/212194A1 |
Compounds of formula (I), wherein the variable substituents are defined herein.
|
|
WO/2022/207924A1 |
The present invention relates to compounds of formula (I). The compounds of the formula (I) are e.g. (S)-1-(5-((pyridin-3-yl)thio) pyrazin-2-yl)-4lH,6'H-spiro[piperidine-4,5'-pyrrolo[l,2-b]py
razol]-4l- amine derivatives and similar comp...
|
|
WO/2022/212748A1 |
The disclosure is in part directed to crystalline forms of (S)-12-fluoro-4-(1-methyl-1H-pyrazol-5-yl)-7a,8,13,14-tetrah
ydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3
-fg][1,4]oxazonine.
|
|
WO/2022/205111A1 |
The present invention discloses a method for preparing an exatecan derivative, and an intermediate thereof. The method comprises a method for preparing a compound of formula (I), and comprises the following steps: in a solvent, performin...
|
|
WO/2022/206888A1 |
The present disclosure provides a compound represented by structural formula (I') or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosur...
|
|
WO/2022/212746A1 |
The disclosure is in part directed to crystalline forms of (S)-12-fluoro-4-(2-methylpyridin-3-yl)-7a,8,13,14-tetrahydro
-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg]
[1,4]oxazonine, free base, and crystalline salt forms of...
|
|
WO/2022/204184A1 |
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
|
|
WO/2022/204720A1 |
Provided herein are compounds of the following structural formula: (I), or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R1, R2, R3, X, Y, m, n,p, Ring G) are as described herein. Compounds of Formul...
|
|
WO/2022/200433A1 |
The present invention relates to a group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine of formula (I) which are inhibitors of HASPIN, whose activity is required for the proliferation of certain tumoral cells, so th...
|
|
WO/2022/199464A1 |
The present invention relates to a series of carbazole derivatives and an application thereof, and an organic electroluminescent element, a display device and a lighting device containing the carbazole derivatives. The structural formula...
|
|
WO/2022/196634A1 |
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), and a light emitting layer (5) that is interposed between the positive electrode (3) and the negative electrode (4), wherein: t...
|
|
WO/2022/194905A1 |
The present invention relates to the compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2022/194976A1 |
Compounds of formula (I) are useful as LRRK2 kinase inhibitors.
|
|
WO/2022/197913A1 |
This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) an...
|
